Načítá se...
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease
BACKGROUND: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn's disease. Long-term efficacy and safety of adalimumab for patients who entered the IMAgINE 2 extension are reported. METHODS: Patients who completed IMAgINE 1 could enroll in IMAg...
Uloženo v:
| Vydáno v: | Inflamm Bowel Dis |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5319394/ https://ncbi.nlm.nih.gov/pubmed/28129288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0000000000001021 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|